12

Modern medicine is faced with an ever-growing number of complex clinical cases that require an integrated approach to diagnosis and treatment. Recent studies have demonstrated a significant increase in the incidence of combined pathology, which creates additional difficulties in choosing the optimal treatment tactics and predicting disease outcomes

  • Количество прочтений 12
  • Дата публикации 08-03-2025
  • Язык статьиIngliz
  • Страницы44-49
English

Modern medicine is faced with an ever-growing number of complex clinical cases that require an integrated approach to diagnosis and treatment. Recent studies have demonstrated a significant increase in the incidence of combined pathology, which creates additional difficulties in choosing the optimal treatment tactics and predicting disease outcomes

№ Название ссылки
1 1.Baskys A., Hou A.C. Vascular dementia: Pharmacological treatment ap-proaches and perspectives. Clin Intervent Aging 2007; 2: 327-335.2.Bes A., Orgogozo J.-M., Poncet M. et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999; 6: 313-322.3.Caraci F., Chisari M., Frasca G. et al. Nicergoline, a drug used for age-de-pendent cognitive impairment, protects cultured neurons against β-amyloid toxicity. Brain Res 2005; 1047: 30-37.4.Cattabeni F. Protein kinase C in synaptic plasticity: A molecular target in the treatment of cognitive disorders. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 6-11.5.Crook T.H. Nicergoline: Parallel evolution of clinical trial methodology and drug development in dementia. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 22-26.6.Giardino L., Giuliani A., Battaglia A. et al. Neuroprotection and aging of the cholinergic system: A role for the ergoline derivative nicergoline (Sermion). Neurosci 2002; 109: 487-497.7.Nappi G., Bono G., Merlo G. et al. Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. Clin Drug Invest 1997; 13: 308-316.8.Pantoni L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci 2004; 226: 67-70.9.Rakhmonova H.N., Rakhmonov Z.M. Innervation Relationships of the Gallbladder Nerve Apparatus with Spinal and Rheumatic Nerve Ganglia (Literature Review).Eurasian Medical Research Periodical,18, 105-108.10.Rakhmonova Kh.N. Morphological bases of innervational connections of the nervous apparatus of the gallbladder Journal of Problems in Biology and Medicine, PBIM 2022 No6 (140), 387-392.11.Saletu B., Anderer P., Semlitsch H.V. Relations between symptomatology and brain function in dementias: Double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline. Dement Geriat Cogn Dis 1997; 8: Suppl 1: 12-21.12.Salimovna S. D. et al. Endothelial dysfunction factor as an indicator of clinical and neurological disorders in pregnant women with preeclampsia //Достижениянаукииобразования. –2019. –No. 11 (52). –С. 55-60.13.Takhirovna J. A., Vladimirovna S. K., Fedorovna V. N. A comprehensive approach to the diagnosis of impaired walking in patients with dyscirculatory encephalopathy //World Bulletin of Public Health. –2023. –Т. 19. –С. 13-17.14.Takhirovna JA, Vladimirovna SK, & Fedorovna VN. A comprehensive approach to the diagnosis of impaired walking in patients with dyscirculatory encephalopathy. World Bulletin of Public Health, 2023;19: 13-17.15.Shmyrina K. V. et al. Experience of using gabagamma in the treatment of chronic nonspecific pain in the lower back //Medicine of Alma Ata. –2016. –Т. 7. –No. 69. –С. 56-60.16.Winblad B., Carfagna N., Bonura L. et al. Nicergoline in dementia. A review of its pharmacological properties and therapeutic potential. CNS Drugs 2000; 14: 267-287.17.Winblad B., Fioravanti M., Dolezal T. et al. Therapeutic use ofnicergoline. Clin Drug Invest 2008; 28: 533-552.
В ожидании